Trade Rhythm Pharmaceuticals Inc - RYTM CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.19 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 59.47 |
| Open | 58.95 |
| 1-Year Change | 46.64% |
| Day's Range | 58.32 - 60.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 14, 2025 | 60.01 | 0.46 | 0.77% | 59.55 | 60.30 | 58.10 |
| Apr 11, 2025 | 59.47 | 1.83 | 3.17% | 57.64 | 60.00 | 55.90 |
| Apr 10, 2025 | 57.72 | -0.48 | -0.82% | 58.20 | 58.83 | 54.73 |
| Apr 9, 2025 | 60.17 | 4.22 | 7.54% | 55.95 | 61.28 | 49.82 |
| Apr 8, 2025 | 57.67 | 0.48 | 0.84% | 57.19 | 62.87 | 56.25 |
| Apr 7, 2025 | 54.92 | 6.87 | 14.30% | 48.05 | 55.77 | 45.77 |
| Apr 4, 2025 | 46.81 | -1.78 | -3.66% | 48.59 | 48.84 | 46.13 |
| Apr 3, 2025 | 49.69 | 0.71 | 1.45% | 48.98 | 50.64 | 48.98 |
| Apr 2, 2025 | 51.86 | 3.60 | 7.46% | 48.26 | 52.22 | 48.26 |
| Apr 1, 2025 | 49.92 | -1.73 | -3.35% | 51.65 | 52.53 | 49.91 |
| Mar 31, 2025 | 52.93 | 0.28 | 0.53% | 52.65 | 53.30 | 51.13 |
| Mar 28, 2025 | 54.75 | 1.62 | 3.05% | 53.13 | 55.09 | 52.65 |
| Mar 27, 2025 | 53.43 | 0.10 | 0.19% | 53.33 | 54.98 | 53.33 |
| Mar 26, 2025 | 54.17 | 1.52 | 2.89% | 52.65 | 54.42 | 52.47 |
| Mar 25, 2025 | 52.86 | 0.20 | 0.38% | 52.66 | 54.41 | 52.54 |
| Mar 24, 2025 | 53.60 | 1.61 | 3.10% | 51.99 | 53.75 | 51.99 |
| Mar 21, 2025 | 51.95 | -1.81 | -3.37% | 53.76 | 54.37 | 51.67 |
| Mar 20, 2025 | 54.13 | 0.98 | 1.84% | 53.15 | 55.24 | 52.72 |
| Mar 19, 2025 | 55.11 | 2.87 | 5.49% | 52.24 | 55.73 | 51.56 |
| Mar 18, 2025 | 52.22 | 0.15 | 0.29% | 52.07 | 52.87 | 51.06 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Rhythm Pharma Company profile
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Rhythm Pharmaceuticals Inc revenues increased from $0K to $3.2M. Net loss decreased 48% to $69.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$3.04 to -$1.40.
| Industry: | Bio Therapeutic Drugs |
222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com